Display options
Cite
Lin RE, Ambler L, Billingslea EN, et al. Electroencephalographic and early communicative abnormalities in Brattleboro rats. Physiol Rep. 2013;1(5):e00100doi: 10.1002/phy2.100.
Lin, R. E., Ambler, L., Billingslea, E. N., Suh, J., Batheja, S., Tatard-Leitman, V., Featherstone, R. E., & Siegel, S. J. (2013). Electroencephalographic and early communicative abnormalities in Brattleboro rats. Physiological reports, 1(5), e00100. https://doi.org/10.1002/phy2.100
Lin, Robert E, et al. "Electroencephalographic and early communicative abnormalities in Brattleboro rats." Physiological reports vol. 1,5 (2013): e00100. doi: https://doi.org/10.1002/phy2.100
Lin RE, Ambler L, Billingslea EN, Suh J, Batheja S, Tatard-Leitman V, Featherstone RE, Siegel SJ. Electroencephalographic and early communicative abnormalities in Brattleboro rats. Physiol Rep. 2013 Oct;1(5):e00100. doi: 10.1002/phy2.100. Epub 2013 Oct 20. PMID: 24303172; PMCID: PMC3841036.
Copy Download .nbib Format: NLM
Share it on

Physiol Rep. 2013 Oct;1(5):e00100. doi: 10.1002/phy2.100. Epub 2013 Oct 20.

Electroencephalographic and early communicative abnormalities in Brattleboro rats.

Physiological reports

Robert E Lin, Lauren Ambler, Eddie N Billingslea, Jimmy Suh, Shweta Batheja, Valerie Tatard-Leitman, Robert E Featherstone, Steven J Siegel

Affiliations

  1. Department of Psychiatry, Translational Neuroscience Program, School of Medicine, University of Pennsylvania Philadelphia, Pennsylvania.

PMID: 24303172 PMCID: PMC3841036 DOI: 10.1002/phy2.100

Abstract

Reductions in the levels of the neuropeptide vasopressin (VP) and its receptors have been associated with schizophrenia. VP is also critical for appropriate social behaviors in humans as well as rodents. One of the prominent symptoms of schizophrenia is asociality and these symptoms may develop prodromally. A reduction in event-related potential (ERP) peak amplitudes is an endophenotype of schizophrenia. In this study, we use the Brattleboro (BRAT) rat to assess the role of VP deficiency in vocal communication during early development and on auditory ERPs during adulthood. BRAT rats had similar vocal communication to wild-type littermate controls during postnatal days 2 and 5 but the time between vocalizations was increased and the power of the vocalizations was reduced beginning at postnatal day 9. During adulthood, BRAT rats had deficits in auditory ERPs including reduced N40 amplitude and reduced low and high gamma intertrial coherence. These results suggest that the role of VP on vocal communication is an age-dependent process. Additionally, the deficits in ERPs indicate an impairment of auditory information processing related to the reduction in VP. Therefore, manipulation of the VP system could provide a novel mechanism for treatment for negative symptoms of schizophrenia.

Keywords: Brattleboro; ERP; USV; schizophrenia; vasopressin

References

  1. Biol Psychiatry. 2011 Jul 1;70(1):28-34 - PubMed
  2. J Psychopharmacol. 2003 Sep;17(3):317-23 - PubMed
  3. Lancet. 1978 Mar 18;1(8064):608 - PubMed
  4. Psychopharmacology (Berl). 2009 Mar;202(4):711-8 - PubMed
  5. Neuroscience. 2006 Sep 1;141(3):1257-64 - PubMed
  6. Brain Res. 1985 Sep 9;342(2):316-22 - PubMed
  7. J Psychopharmacol. 2010 Mar;24(3):407-19 - PubMed
  8. Nicotine Tob Res. 2010 Jun;12(6):589-97 - PubMed
  9. Psychoneuroendocrinology. 1992 Nov;17(6):611-7 - PubMed
  10. Eur J Pharmacol. 1993 Mar 16;233(1):101-7 - PubMed
  11. Dialogues Clin Neurosci. 2012 Sep;14(3):263-79 - PubMed
  12. Peptides. 1983 Jul-Aug;4(4):421-4 - PubMed
  13. Psychopharmacology (Berl). 1984;84(4):566-8 - PubMed
  14. Acta Psychiatr Scand. 2011 Feb;123(2):125-35 - PubMed
  15. Neuropsychobiology. 1989;20(3):113-9 - PubMed
  16. PLoS One. 2012;7(7):e39775 - PubMed
  17. Prog Brain Res. 1998;119:351-64 - PubMed
  18. Neuroscience. 2007 Jan 5;144(1):239-46 - PubMed
  19. Brain Res Bull. 2010 Sep 30;83(3-4):147-61 - PubMed
  20. Behav Neurosci. 2008 Oct;122(5):982-90 - PubMed
  21. Neuroendocrinology. 1980;30(3):174-7 - PubMed
  22. World J Biol Psychiatry. 2013 Sep;14(7):478-89 - PubMed
  23. JAMA Psychiatry. 2013 Mar;70(3):261-70 - PubMed
  24. Peptides. 1983 Sep-Oct;4(5):717-20 - PubMed
  25. Behav Brain Res. 2009 Jan 30;197(1):166-77 - PubMed
  26. Biol Psychiatry. 2010 Dec 15;68(12):1100-6 - PubMed
  27. Eur J Pharmacol. 2008 Apr 7;583(2-3):226-42 - PubMed
  28. Neuropsychopharmacology. 2003 Sep;28(9):1597-605 - PubMed
  29. Schizophr Res. 2013 Feb;143(2-3):348-53 - PubMed
  30. Genes Brain Behav. 2009 Oct;8(7):661-75 - PubMed
  31. J Psychopharmacol. 2011 Jun;25(6):836-41 - PubMed
  32. PLoS Biol. 2005 Dec;3(12):e386 - PubMed
  33. Neuropsychobiology. 1986;15(3-4):114-21 - PubMed
  34. Biol Psychiatry. 2013 Jul 15;74(2):122-9 - PubMed
  35. Genes Brain Behav. 2008 Apr;7(3):344-54 - PubMed
  36. Dev Neurosci. 2012;34(2-3):240-9 - PubMed
  37. Behav Brain Res. 2012 Oct 1;234(2):233-7 - PubMed
  38. Psychophysiology. 2012 Apr;49(4):522-30 - PubMed
  39. Lancet. 1979 Dec 8;2(8154):1245-6 - PubMed
  40. J Neurol Neurosurg Psychiatry. 1985 Jan;48(1):50-7 - PubMed
  41. J Pharmacol Exp Ther. 2008 Jul;326(1):230-9 - PubMed
  42. Psychiatr Danub. 2011 Sep;23 Suppl 1:S118-22 - PubMed
  43. Horm Behav. 2006 Apr;49(4):501-8 - PubMed
  44. Pharmacol Biochem Behav. 2005 Dec;82(4):652-7 - PubMed
  45. Prog Brain Res. 1992;93:455-60; discussion 461 - PubMed
  46. Behav Neurosci. 2012 Apr;126(2):332-43 - PubMed
  47. Brain Res. 2003 Nov 28;992(1):85-95 - PubMed
  48. Int J Dev Neurosci. 2009 Apr;27(2):175-83 - PubMed
  49. Physiol Behav. 1986;36(4):713-21 - PubMed
  50. Neuroscience. 2004;129(1):101-7 - PubMed
  51. Schizophr Res. 2010 Dec;124(1-3):110-8 - PubMed
  52. Biol Psychiatry. 2007 Jan 1;61(1):23-30 - PubMed
  53. Schizophr Bull. 2007 Jan;33(1):69-94 - PubMed
  54. Arch Gen Psychiatry. 2011 Jul;68(7):654-64 - PubMed
  55. Schizophr Res. 2013 May;146(1-3):95-102 - PubMed
  56. Brain Res. 2009 Aug 4;1283:58-64 - PubMed
  57. Biol Psychiatry. 2006 Dec 1;60(11):1278-81 - PubMed
  58. Neuroscience. 2009 Jan 23;158(2):705-12 - PubMed
  59. Prog Brain Res. 1998;119:619-43 - PubMed
  60. Pharmacol Biochem Behav. 2008 Jan;88(3):341-8 - PubMed
  61. Physiol Behav. 1994 Jan;55(1):145-9 - PubMed
  62. Neurochem Res. 2004 Jun;29(6):1179-88 - PubMed
  63. Neurobiol Dis. 2012 Apr;46(1):93-100 - PubMed
  64. Clin Neurophysiol. 2010 Aug;121(8):1233-9 - PubMed
  65. Brain Res Bull. 1981 Jan;6(1):71-5 - PubMed
  66. Dev Psychobiol. 2009 Mar;51(2):158-72 - PubMed
  67. Genes Brain Behav. 2012 Aug;11(6):740-50 - PubMed
  68. Neurosci Biobehav Rev. 2009 Apr;33(4):508-15 - PubMed
  69. Neuroscience. 2005;133(3):729-38 - PubMed
  70. Neurosci Lett. 1982 Jan 22;28(1):87-92 - PubMed
  71. Ann N Y Acad Sci. 1982;394:672-88 - PubMed
  72. Schizophr Res. 2012 Sep;140(1-3):250-7 - PubMed
  73. Schizophr Bull. 2009 May;35(3):549-62 - PubMed
  74. Jpn J Psychiatry Neurol. 1989 Jun;43(2):161-9 - PubMed
  75. Psychoneuroendocrinology. 2009 Jul;34(6):901-8 - PubMed
  76. Eur Arch Psychiatry Neurol Sci. 1984;234(3):162-5 - PubMed
  77. Br J Psychiatry. 1985 Dec;147:696-701 - PubMed
  78. Neuropsychopharmacology. 2009 Jul;34(8):2011-8 - PubMed
  79. Neurosci Lett. 1993 Apr 16;153(1):103-6 - PubMed
  80. Curr Opin Neurobiol. 2012 Jun;22(3):537-44 - PubMed
  81. Psychopharmacology (Berl). 2009 Mar;202(4):745-51 - PubMed
  82. J Neurosci. 2013 Feb 20;33(8):3276-83 - PubMed
  83. Front Psychiatry. 2011 Oct 24;2:56 - PubMed
  84. Neurosci Behav Physiol. 2006 Sep;36(7):749-54 - PubMed
  85. Horm Behav. 2007 Mar;51(3):395-405 - PubMed
  86. Psychiatry Res. 2009 Jan 30;165(1-2):27-37 - PubMed
  87. Curr Opin Neurobiol. 2013 Jun;23(3):310-7 - PubMed

Publication Types